AI-generated price forecast for AbbVie (ABBV) across 1-hour, 4-hour, daily and weekly horizons — updated continuously, with a public accuracy track record.
As of October 2026: K3vl4r's AI model currently reads ABBV as 2/2 bearish · strong across its horizons (0 of 2 timeframes pointing up), with a last price of 260.54. See our public, auditable track record →
Last price
260.54
AI outlook
2/2 bearish · STRONG
Timeframes up
0 / 2
| Horizon | Direction | Projected move (end of horizon) | Bullish prob. |
|---|---|---|---|
| 1-hour | — | — | — |
| 4-hour | — | — | — |
| Daily~3 months out | ▼ Down | -19.95% | 0% |
| Weekly~1.8 years out | ▼ Down | -30.78% | — |
Public STOCK Act disclosures · amounts are ranges, reported up to ~45 days after the trade.
| Member | Action | Date | Amount |
|---|---|---|---|
| Pete Sessions | ▼ Sell | 2026-09-14 | $15001–50000 |
| Josh Gottheimer (joint) | ▼ Sell | 2026-05-05 | $1001–15000 |
| Alan Armstrong | ▲ Buy | 2026-03-27 | $15001–50000 |
| Julie Johnson (joint) | ▼ Sell | 2025-12-18 | $1001–15000 |
| Julia Letlow | ▼ Sell | 2025-12-08 | $1001–15000 |
9 disclosures in the last year. Track what Congress is trading across the whole market in the app — get started free.
From the market-news feed the forecasts are read against.
🔒
See the full ABBV forecast
Interactive forecast chart, price targets, and Monte-Carlo confidence bands — plus the daily AI Top Picks book. Free to start, no card required.
Create a free account →Already have one? Log in
K3vl4r's AI model currently reads ABBV as 2/2 bearish · STRONG — 0 of 2 forecast horizons point up, so the overall read is leaning to the downside. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.
K3vl4r's model projects ABBV toward $259.76 over the next ~3 months, a -0.2% move from $260.28. Projections update continuously as new data arrives and are inherently uncertain. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.
Over its longest horizon (~~1.8 years), the model's projected target for ABBV is $260.78 (-0.3% vs $261.59). Confidence decreases the further out the horizon, so treat longer-range targets as one scenario, not a guarantee. This is a model-generated forecast for information only — not investment advice, and forecasts may be inaccurate.
Part of Biotech & Pharma forecasts — browse the full sector.
Or see the full ABBV price prediction (2027–2040), or the forecast for today, tomorrow and this week.
Curious how this is generated? Read how K3vl4r forecasts — the model, the confidence bands, and what we deliberately do not claim.
K3vl4r publishes a public, auditable track record of its Daily Top Picks — see the live results.
Forecasts are model-generated estimates for informational purposes only and are not financial advice. Markets are risky; past accuracy does not guarantee future results. See our Risk Disclosure.